B43-PAP IMMUNOTOXIN COMBINED WITH STANDARD 4 DRUG INDUCTION FOR CD+ ALL

CCG 0957是一项I期研究，目的是在以下情况下确定B43-PAP的毒性 与标准的四药再诱导同时给予(长春新碱， 强的松、L的天冬酰胺酶、柔红霉素)治疗儿童急性白血病 淋巴细胞白血病(ALL)。B43-PAP是一种免疫毒素(单抗 抗体-毒素结合物)已经研究了9年 儿童癌症组织免疫毒素资源的法提赫·乌肯博士 明尼阿波利斯的实验室。已经完成了单一机构的研究 在明尼苏达大学。B43为所选的单抗 因为它是针对CD19抗原的，而CD19抗原 显示前B血统ALL的特异性-最常见的类型 儿童中的白血病。

CCG 0957 is a phase-I study to determine the toxicity of B43-PAP when given concurrently with a standard four drug re-induction (Vincristine, Prednisone, L'Asparaginase, Daunomycin) in pediatric patients with acute lymphoblastic leukemia (ALL). B43-PAP is an immunotoxin (monoclonal antibody-toxin conjugate) which has been studied for the past 9 years by Dr. Fatih Uckun at the Children's Cancer Group Immunotoxin Resource Laboratory in Minneapolis. Single institution studies have been done at the University of Minnesota. B43 is the monoclonal antibody selected for the protocol because it is targeted toward the CD19 antigen, which displays specificity for pre-B lineage ALL - the most common type of leukemia in children.